The current prospective comparative phase 2 study aimed to assess the role of intravenous L-alanyl L-Glutamine in reducing the rate of oral mucositis for squamous head and neck cancer patients receiving radiotherapy with or without concurrent chemotherapy.
From September 2014 to Septemper 2016, 100 head and neck cancer patients were treated with radiotherapy or combined chemo-radiation at the Clinical Oncology Department, Tanta University Hospitals. Patients were randomized in 1:1 ratio into Group A (n = 50 patients) treated by radiotherapy or concurrent chemo-radiotherapy and Group B (n = 50 patients) to receive same treatment in addition to intravenous Glutamine. The investigational drug was infused daily at dose of 0.3-0.4 g/kg diluted in NS and administered at rate of 0.1g/Kg/hr. All patients received total dose of 65-70 Gy using Linac 6MV photon beam supplemented with electron beam when needed. For concurrent chemotherapy, Cisplatin (40mg/m2) was administered weekly.
Mucositis was assessed by WHO grading system. A significantly higher incidence of mucositis was reported in 45% of Group A patients compared with patients in group B who received glutamine 10% P
Intravenous L-alanyl L-Glutamine may be an effective measure to lower incidence or prevention of oral mucositis in head and neck cancer patients treated by radiotherapy or combined chemo-radiation.
Clinical trial identification
Legal entity responsible for the study
Tanta University Hospital
All authors have declared no conflicts of interest.